Clene Inc.
As of Oct 22, 2026, Clene is in Stage 4, the downtrend phase, now in week 15 (since Jul 14, 2026). It closed at $3.88, 69.0% below its 52-week high and below its 200-day average, which is falling.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CLNN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CLNN among Packaged Foods46th of 65 by relative strength
All 65 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | DAR | Stage 2 · wk 10 | 93 | −9.3% |
| 2 | WEST | Stage 2 · wk 4 | 93 | +19.9% |
| 3 | HLF | Stage 1 · wk 2 | 89 | +14.9% |
| 4 | SENEB | Stage 2 · wk 34 | 87 | −4.8% |
| 5 | CENT | Stage 3 · wk 6 | 84 | +14.3% |
| 6 | SENEA | Stage 2 · wk 38 | 81 | −8.3% |
| 7 | CENTA | Stage 3 · wk 6 | 81 | +13.6% |
| 8 | SJM | Stage 2 · wk 17 | 78 | +9.0% |
| …46 | CLNN | Stage 4 · wk 15 | 21 | −9.6% |
Clene: quick answers
What stage is Clene in?
As of Oct 22, 2026, Clene (CLNN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 14, 2026 and is in week 15. What the four stages mean
Is Clene in an uptrend?
No. Clene is in a Stage 4 downtrend. It trades 25.9% below its 200-day average, which is falling.
How far is Clene from its 52-week high?
Clene closed at $3.88 on Oct 22, 2026, 69.0% below its 52-week high of $12.50. Its 52-week low is $3.10.
How has Clene performed over the past year?
As of Oct 22, 2026, Clene is down 55.0% over the past year and down 32.8% so far in 2026.
Which sector and industry is Clene in?
Clene is in the Packaged Foods industry, part of the Consumer Staples sector.
About this companyConsumer Staples· Packaged Foods
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.